Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
IDEAYA Biosciences ( (IDYA) ) has provided an announcement.
On June 24, 2025, IDEAYA Biosciences held its Annual Meeting of Stockholders where three proposals were voted on. The election of two Class III directors, ratification of PricewaterhouseCoopers LLP as the independent auditor, and approval of executive compensation were addressed. The election saw Jeffrey L. Stein, Ph.D., and Scott W. Morrison nominated, with Stein receiving more votes. The ratification of the auditor was largely uncontested, and the executive compensation received a majority vote in favor, indicating shareholder support for the company’s leadership and financial oversight.
The most recent analyst rating on (IDYA) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.
Spark’s Take on IDYA Stock
According to Spark, TipRanks’ AI Analyst, IDYA is a Neutral.
IDEAYA Biosciences’ stock score is primarily impacted by its financial performance challenges, including declining revenues and net losses. Positive technical indicators provide some support, indicating potential short-term momentum. However, the lack of profitability and valuation concerns weigh heavily on the overall score.
To see Spark’s full report on IDYA stock, click here.
More about IDEAYA Biosciences
IDEAYA Biosciences, Inc. operates in the biotechnology industry, focusing on the development of precision medicine and immuno-oncology therapies. The company is engaged in discovering and developing targeted therapeutics for cancer treatment, emphasizing synthetic lethality and direct targeting of oncogenic pathways.
Average Trading Volume: 1,433,738
Technical Sentiment Signal: Sell
Current Market Cap: $1.9B
For detailed information about IDYA stock, go to TipRanks’ Stock Analysis page.